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myeloproliferative disorder (MPD) polycy-
themia vera, in which erythropoiesis is
characteristically elevated, there is a sig-
nificant decline in the levels of miR-150
(Bruchova et al., 2007). This is clearly con-
sistent with the experimental observations
made by Lu et al., but it is also intriguing in
that it suggests that the miR-150/MYB
axis could be a critical factor in MPDs.
Indeed, the mouse models of reduced
MYB activity all demonstrate features of
MPD characterized by elevated platelet
numbers, and it can be speculated that
increased miR-150/decreased MYB ex-
pression may contribute to the disease
phenotype. Whether or not miR-150
and MYB are directly implicated in the
initiation or progression of such MPDs,
their impact on commitment nevertheless
suggests possible strategies for therapeu-
tic intervention.
Many questions remain regarding the
control of MEP commitment by miRNAs.
What other genes does miR-150 regu-
late? Do other miRNAs have a role, both
in MYB expression and that of other
targets? How are the miRNA levels them-
selves regulated? It will also be important
to determine why MYB is a critical target
of miR-150; that is, what genes does it
regulate, especially if its role is one of
controlling commitment? Another impor-
tant step will be to determine how MYB
activity in the MEP and following lineage
commitment integrates with the many
transcriptional regulators that are already
known to be important for erythroid and/
or megakaryocytic gene expression (e.g.,
GATA-1, EKLF, STAT5, SCL, NF-E2, and
Fli1, to mention but a few). The answers
to these questions will require some so-
phisticated gene expression analysis of
purified MEPs undergoing conditional
alteration of MYB activity. With this infor-
mation in hand it will be interesting to
determine if other hematopoietic progen-
itors and stem cells, all of which express
MYB, are similarly regulated with respect
to their commitment toward specific dif-
ferentiated fates.
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When phosphorylated by mTORC1/S6K, the insulin receptor substrate (IRS-1) is targeted for ubiquitination
and proteasomal degradation. In a recent issue ofMolecular Cell, Xu et al. reveal that the E3 ubiquitin-ligase
CUL7/Fbw8 targets IRS-1 for degradation, thereby implicating this enzyme in the regulation of insulin
signaling.The insulin-phosphoinositide 3-kinase
(PI3K) pathway regulates diverse pro-
cesses including glucose homeostasis,
survival, and growth. Aberrant regulation
of this pathway can lead to the develop-
ment of Type 2 diabetes or cancer; there-
fore, regulating PI3K signaling represents
an important element of metabolic control.816 Developmental Cell 14, June 2008 ª200To activate PI3K, the activated insulin re-
ceptor recruits phosphotyrosine-binding
adaptors, the IRS proteins. Subsequently
PI3K activates mTORC1, a nutrient-sens-
ing protein kinase that regulates cell
growth. Activated mTORC1, via its sub-
strate the kinase S6K, is known to posi-
tively regulate translational initiation but8 Elsevier Inc.also acts negatively via a feedback loop
to inhibit IRS abundance (Figure 1),
thereby ensuring a limitation of PI3K
signaling (Harrington et al., 2004). IRS-1
inhibition occurs at both transcriptional
and posttranslational levels (Harrington
et al., 2005), including ubiquitin-media-
ted proteolysis by SOCS1/3-containing
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2 for destruction (Rui et al., 2002). In a re-
cent issue of Molecular Cell, Xu et al.
(2008) identify the E3 ubiquitin-ligase
CUL7/Fbw8 as a new player in the
mTORC1-mediated turnover of IRS-1.
CUL7 belongs to the cullin family of
scaffold proteins and interacts with the
substrate-recognizing Skp1-Fbw8 F-box
heterodimer and the RING finger protein
ROC1 to form an E3-ubiquitin ligase
(Pintard et al., 2004). To identify targets
of CUL7, Xu et al. used a proteomic ap-
proach in which they analyzed proteins
that interact with Fbw8. This approach
led them to IRS-1, and degradation by
CUL7/Fbw8 appears to be IRS-1 specific
as it does not target the related adaptor
IRS-2. Thus, although IRS-2 is also sub-
ject to mTORC1-regulated degradation
during chronic insulin/IGF-1 stimulation
(Harrington et al., 2005), its degradation
must be via a distinct E3-ligase.
Xu et al. show that IRS-1 degradation
by Fbw8 is reversed by the mTORC1
inhibitor rapamycin. How then does
mTORC1 regulate the ability of IRS-1 to
act as a substrate of this complex? Given
that S6K potentiated the interaction be-
tween Fbw8 and IRS-1 and stimulated
the polyubiquitination of IRS-1 in vitro,
the most likely mechanism appears to
be via S6K-mediated phosphorylation of
IRS-1 acting as a recognition signal for
Fbw8. However, the authors found that
nonphosphorylatable mutants of IRS-1,
including those in which the two predom-
inant S6K phosphorylation sites (Ser307
and Ser312, adjacent to the phosphotyro-
sine binding domain of IRS-1) were mu-
tated and were still susceptible to degra-
dation. However, a combined mutant of
five phosphorylation sites was partially
resistant to CUL7/Fbw8-mediated prote-
olysis. Since a truncation mutant encom-
passing residues 1–574 was degraded
by CUL7/Fbw8, whereas a smaller trun-
cated protein (residues 1-522) was not,
one possibility is that the recognition
of IRS-1 by CUL7/Fbw8 may be via
combined phosphorylation of Ser307/
Ser312/Ser527 inducing some structuralchange in a region between aa 522–574
involved in binding Fbw8.
Previous evidence for the CUL7 E3-
ligase playing a role in insulin signaling in-
dicated that IGFBP-2—a secreted protein
that inhibits IGF-1 (and IGF-2) actions—is
overexpressed in mouse embryonic fibro-
blasts (MEFs) lacking CUL7 or Fbw8
(Tsutsumi et al., 2008). In the light of in-
creased PI3K signaling in CUL7-deficient
MEFs, this upregulation of IGFBP-2 might
possibly represent a negative feedback
mechanism (or adaptation) acting to re-
duce receptor activation. In addition, a
distinct cullin E3 ligase, CUL4/Fbw5, has
recently been reported to target a negative
regulator of insulin signaling, TSC2, for
degradation (Hu et al., 2008).
Interestingly, Xu et al. show that CUL7-
deficient MEFs undergo premature senes-
cence and argue that this might be due to
aberrant IRS-1 protein level, activating Akt
and/or ERK and inducing a senescence
stimulus. However, as it was not possible
to rescue senescence by suppressing
IRS-1 abundance, it is plausible that
CUL7 substrates other than IRS-1 are re-
sponsible. CUL7 also binds to p53, which,
although not apparently a direct substrate,
Figure 1. Restraining Insulin/PI3K Signaling
via mTORC1/S6K
Insulin-induced recruitment and activation of IRS-1
leads to PI3K/Akt activation of the mTOR/S6K
pathway: this, in turn, downregulates insulin/PI3K
signaling by (1) transcriptional regulation (through
an unknown target of S6K) and (2) phosphorylation.
Phosphorylation prevents the interaction between
IRS-1 and the insulin receptor (InR) and also tar-
gets IRS-1 to the CUL7 E3 ligase, leading to its
ubiquitination and destruction by the proteasome.Developmentais repressed as a transcriptional activator
by CUL7 (Andrews et al., 2006). Thus,
a potential derepression of p53 function
in CUL7-deficient MEFs might also ex-
plain their reduced proliferation. CUL7/
Fbw8 deficiency causes growth retarda-
tion and neonatal lethality in mice (Tsut-
sumi et al., 2008; Arai et al., 2003), and in
humans, CUL7 mutations are found in
3-M syndrome, which is characterized by
pre- and postnatal growth retardation
(Huber et al., 2005). It will be interesting
to determine whether there is a link be-
tween senescence and these in vivo
phenotypes of CUL/Fbw8 deficiency. Un-
doubtedly, further proteomic analyses will
reveal the full range of substrates targeted
by this intriguing E3-ubiquitin ligase and
shed further light on its role in proliferation
and signaling.
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